Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,841 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 822 · Balance 37,297 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,019 · Balance 38,316 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 2,255 · Balance 40,571 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 4 · 2026-09-15 · Sale · Disposed 4,730 · Balance 35,841 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2029-11-20 | Direct | 6,574 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 822 · Balance 6,574 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31 | Direct | 8,144 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 1,019 · Balance 8,144 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14 | Direct | 18,032 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,255 · Balance 18,032 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2022 Filed Jul 18, 2022 22:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,000 | $24.40 | $146,373.60 |
DisclosureSEC source: 0001567619-22-014131 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,208 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $24.24 to $24.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-012144 · doc1.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,478 Underlying: Common Stock · 2,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $20.62 | $51,538.50 |
DisclosureSEC source: 0001567619-22-012144 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.285 to $20.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,500 | $1.68 | $4,201.50 |
DisclosureSEC source: 0001567619-22-012144 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 11,796 | $0.00 Strike: $20.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012317 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 Underlying: Common Stock · 11,796 shares Expires 2032-06-01 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012317 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,208 F1 · balance_after: Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,004 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-009441 · doc1.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,978 Underlying: Common Stock · 1,004 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,496 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-22-009441 · doc1.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,110 Underlying: Common Stock · 1,496 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option began vesting monthly over 48 months beginning July 11, 2018, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $20.44 | $51,112.00 |
DisclosureSEC source: 0001567619-22-009441 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.13 to $20.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,004 | $1.68 | $1,687.32 |
DisclosureSEC source: 0001567619-22-009441 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,496 | $0.58 | $867.98 |
DisclosureSEC source: 0001567619-22-009441 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 20:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-22-007865 · doc1.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,606 Underlying: Common Stock · 7,500 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option began vesting monthly over 48 months beginning July 11, 2018, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 20:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,500 | $20.02 | $150,183.75 |
DisclosureSEC source: 0001567619-22-007865 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.00 to $20.135, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 20:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 7,500 | $0.58 | $4,351.50 |
DisclosureSEC source: 0001567619-22-007865 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-22-000625 · doc1.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,106 Underlying: Common Stock · 2,500 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $21.21 | $53,029.50 |
DisclosureSEC source: 0001567619-22-000625 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.66 to $21.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,500 | $0.58 | $1,450.50 |
DisclosureSEC source: 0001567619-22-000625 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 23, 2021 Filed Dec 24, 2021 02:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000899243-21-049728 · doc4.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,606 Underlying: Common Stock · 2,500 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 23, 2021 Filed Dec 24, 2021 02:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $20.16 | $50,395.50 |
DisclosureSEC source: 0000899243-21-049728 · doc4.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.00 to $20.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 23, 2021 Filed Dec 24, 2021 02:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,500 | $0.58 | $1,450.50 |
DisclosureSEC source: 0000899243-21-049728 · doc4.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-21-019290 · doc1.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,106 Underlying: Common Stock · 2,500 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $21.81 | $54,524.00 |
DisclosureSEC source: 0001567619-21-019290 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $21.31 to $22.26, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,500 | $0.58 | $1,450.50 |
DisclosureSEC source: 0001567619-21-019290 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 18:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-21-017896 · doc1.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,606 Underlying: Common Stock · 2,500 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 18:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $23.87 | $59,679.75 |
DisclosureSEC source: 0001567619-21-017896 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $23.23 to $24.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 18:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,500 | $0.58 | $1,450.50 |
DisclosureSEC source: 0001567619-21-017896 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,444 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-016752 · doc1.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,223 Underlying: Common Stock · 4,444 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 556 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-21-016752 · doc1.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,106 Underlying: Common Stock · 556 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 800 | $21.28 | $17,020.00 |
DisclosureSEC source: 0001567619-21-016752 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $21.09 to $21.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,200 | $20.71 | $86,966.46 |
DisclosureSEC source: 0001567619-21-016752 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,696 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.33 to $21.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 4,444 | $1.68 | $7,468.59 |
DisclosureSEC source: 0001567619-21-016752 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 556 | $0.58 | $322.59 |
DisclosureSEC source: 0001567619-21-016752 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,028 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · derivative · entry 9 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,862 Underlying: Common Stock · 1,028 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests monthly over a four year period beginning November 20, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 781 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · derivative · entry 8 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,428 Underlying: Common Stock · 781 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 391 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,933 Underlying: Common Stock · 391 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 250 | $26.87 | $6,718.50 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · nonDerivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $26.76 to $27.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,950 | $26.03 | $50,757.33 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,146 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $25.70 to $26.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,028 | $6.52 | $6,704.62 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 781 | $1.68 | $1,312.55 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 391 | $1.68 | $657.11 |
DisclosureSEC source: 0001567619-21-013033 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:38 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 13,391 | $0.00 Strike: $27.77 | $0.00 |
DisclosureSEC source: 0001567619-21-012029 · doc1.xml · derivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 Underlying: Common Stock · 13,391 shares Expires 2031-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,029 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · derivative · entry 9 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,890 Underlying: Common Stock · 1,029 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests monthly over a four year period beginning November 20, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 781 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · derivative · entry 8 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,209 Underlying: Common Stock · 781 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 390 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,324 Underlying: Common Stock · 390 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 142 | $27.61 | $3,920.22 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · nonDerivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,553 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $27.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,058 | $27.06 | $55,682.48 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,695 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $26.50 to $27.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,029 | $6.52 | $6,711.14 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 781 | $1.68 | $1,312.55 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 390 | $1.68 | $655.43 |
DisclosureSEC source: 0001567619-21-011609 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 21, 2021 Filed May 25, 2021 19:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,222 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-21-011126 · doc1.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,552 Underlying: Common Stock · 1,222 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F5 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.